Helus Pharma Names Former Pfizer CMO Freda Lewis-Hall to Board and Scientific Advisory Role

Helus Pharma ( (HELP) ) just unveiled an announcement.

Helus Pharma has appointed former Pfizer executive Dr. Freda Lewis-Hall to its board of directors and as chair of its Scientific Advisory Committee, bringing more than 40 years of experience in psychiatry, biopharmaceutical leadership, and public health. The move is expected to strengthen Helus’ clinical development strategy, regulatory engagement, and scientific governance as it advances its novel serotonergic agonist portfolio toward commercialization and seeks greater recognition in the mental health therapeutics market.

Dr. Lewis-Hall, who previously served as Pfizer’s chief medical officer and chief patient officer and helped guide SpringWorks Therapeutics from spinout to commercial stage and eventual multi-billion-dollar acquisition, will advise Helus on discovery opportunities, clinical strategy, and regulatory pathways. Her appointment underscores the company’s emphasis on patient outcomes, disciplined execution, and long-term value creation for stakeholders as it builds its position in the psychiatric drug development landscape.

The most recent analyst rating on (HELP) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Helus Pharma stock, see the HELP Stock Forecast page.

More about Helus Pharma

Helus Pharma is a clinical-stage pharmaceutical company listed on Nasdaq and Cboe Canada that is developing novel serotonergic agonists for serious mental health conditions. The company focuses on advancing a pipeline of psychiatric treatments that emphasize strong clinical design, reproducibility, and regulatory clarity to address significant unmet needs in global mental health care.

Average Trading Volume: 668,958

Technical Sentiment Signal: Sell

Current Market Cap: $1.4M

See more data about HELP stock on TipRanks’ Stock Analysis page.